Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 09, 2022 08:10 ET | Source: Pharvaris N.V.

Pharvaris to Participate in 11th Annual SVB Leerink Global Healthcare Conference

ZUG, Switzerland, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor...
December 22, 2021 08:10 ET | Source: Pharvaris N.V.

Pharvaris Announces Changes to its Board of Directors

ZUG, Switzerland, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor...
December 07, 2021 08:10 ET | Source: Pharvaris N.V.

Pharvaris Announces Changes to its Board of Directors

ZUG, Switzerland, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor...
November 10, 2021 08:10 ET | Source: Pharvaris N.V.

Pharvaris Reports Third Quarter 2021 Financial Results and Provides Business Highlights

RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks, proceeding; topline data reaffirmed for 2022CHAPTER-1, Phase 2 prophylactic study of PHVS416 for the prevention of HAE...
September 03, 2021 08:00 ET | Source: Pharvaris N.V.

Pharvaris to Participate in Upcoming September Investor Conferences

ZUG, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor...
July 30, 2021 08:00 ET | Source: Pharvaris N.V.

Pharvaris Reports Second Quarter 2021 Financial Results and Provides Business Highlights

RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks expanding to US, expected to report data in 2022 CHAPTER-1, Phase 2 prophylactic study of PHVS416 for the prevention of...
July 09, 2021 18:10 ET | Source: Pharvaris N.V.

Pharvaris Presents Clinical Data on Oral PHA121 Supporting the Prophylactic Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021

ZUG, Switzerland, July 10, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor...
July 01, 2021 07:00 ET | Source: Pharvaris N.V.

Pharvaris to Present PHA121 Clinical Data for Oral Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021

ZUG, Switzerland, July 01, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor...
June 11, 2021 08:00 ET | Source: Pharvaris N.V.

Pharvaris Announces Annual Meeting of Shareholders

ZUG, Switzerland, June 11, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor...
June 04, 2021 03:45 ET | Source: Pharvaris N.V.

Pharvaris Presents Pharmacokinetic and Pharmacodynamic Data for Oral PHA121, Under Development for the Treatment of HAE, at 12th C1 Inhibitor Deficiency and Angioedema Workshop

ZUG, Switzerland, June 04, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor...